FAGR Fagron NV

EBR · BE · Healthcare · Drug Manufacturers - Specialty & Generic · fagron.com

22.65EUR+0.67%Mkt Cap: 1.81B $P/E: 18.12Today

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compoundi…

Industry Peers

Drug Manufacturers - Specialty & Generic

Takeda Pharmaceutical Company Limited

$56.90BUSD

TEVA

Teva Pharmaceutical Industries Limited

United Therapeutics Corporation - Common Stock

$23.23BUSDP/E 19.4

VTRS

Viatris Inc. - Common Stock

$20.22BUSD

SOBI

Swedish Orphan Biovitrum AB (publ)

$14.14BUSDP/E 110.6

NBIX

Neurocrine Biosciences, Inc. - Common Stock

Elanco Animal Health Incorporated

$11.25BUSD

RDY

Dr. Reddy's Laboratories Limited

Amneal Pharmaceuticals, Inc. - Class A Common Stock

$7.07BUSDP/E 42.3

ALKS

Alkermes plc - Ordinary Shares

$7.00BUSDP/E 109.9

HIMS

Hims & Hers Health, Inc.

$6.92BUSD

LNTH

Lantheus Holdings, Inc. - Common Stock

$6.53BUSDP/E 23.9

KNSA

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

$5.83BUSDP/E 76.6

INDV

Indivior Pharmaceuticals, Inc. - Common Stock

$4.21BUSDP/E 12.8

Key Statistics

Company

Market Cap1.81B USD

Enterprise Value2.35B USD

Revenue (TTM)1.12B USD

Gross Profit469.57M USD

Net Income (TTM)98.93M USD

Revenue/Share14.04 EUR

Last Price22.65 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees4.9K

CountryBE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISINBE0003874915

Valuation

P/E (Trailing)18.12

P/E (Forward)13.52

PEG15.84

EV/EBITDA12.38

EV/Revenue2.10

P/S1.61

P/B2.78

EPS (TTM)1.25

EPS (Forward)1.66

52W Range

19.7253% of range25.30

52W High25.30 EUR

52W Low19.72 EUR

Profitability

Gross Margin45.37%

Oper. Margin13.72%

EBITDA Margin16.98%

Profit Margin9.56%

ROE16.50%

ROA7.32%

Growth

Revenue Growth16.00%

Earnings Growth1.60%

Cash Flow & Leverage

Operating CF168.76M USD

CapEx (TTM)33.27M USD

FCF Margin6.54%

FCF Yield4.05%

Net Debt550.47M USD

Net Debt/EBITDA2.90

Balance Sheet

Debt/Equity0.85

Current Ratio1.77

Quick Ratio1.02

Book Value/Sh8.11 EUR

Cash/Share1.79 EUR

Dividends

Fwd Div Rate0.40 EUR

Trail. Div Rate0.40 EUR

Div. Yield1.78%

5Y Avg Yield1.48%

Payout Ratio32.00%

Ex-Div DateMay 18, 2026

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)29.08 EUR

Upside (mean)+28.4%

Target Range27.50 EUR – 31.00 EUR

27.50+28.4% to mean31.00

# Analysts6

Ownership

Shares Out.73.39M

Float65.85M

Insiders0.30%

Institutions71.98%

Technical

SMA 5022.30 (+1.6%)

SMA 20022.87 (-1.0%)

Beta0.38

S&P 52W Chg14.58%

Avg Vol (30d)94.06K

Avg Vol (10d)100.19K

Technical Indicators

RSI (14)52.9

MACD0.1293

MACD Signal-0.0097

MACD Hist.+0.1390

BB Upper23.26 EUR

BB Middle21.99 EUR

BB Lower20.72 EUR

BB Width11.54%

ATR (14)0.5170 EUR

Vol Ratio (20d)0.68x